Latest update (checked October 2, 2026): The federal GLP-1 gastrointestinal injury litigation, MDL No. 3094, is still in the pretrial stage. Judge Karen Marston held an evidentiary hearing on expert testimony from September 14 to 18, 2026, covering warnings, preemption, and general causation. As of late September, no ruling had been announced, and summary judgment motions on several injury categories are still pending. The MDL listed 4,022 pending cases as of September 1, 2026. No bellwether trial date has been set and no settlement program has been announced. Vision loss claims now run separately in MDL No. 3163. We’ll update this page when the court rules.
Last updated: October 2026
The GLP-1 lawsuit is one of the largest pharmaceutical injury cases in the country right now, with thousands of people suing Novo Nordisk and Eli Lilly over serious side effects tied to drugs like Ozempic, Wegovy, and Mounjaro.
These aren’t minor complaints. People are reporting stomach paralysis, pancreatitis, vision loss, and intestinal blockages that required hospitalization and surgery.
If you or someone you know used a GLP-1 drug and got seriously hurt, 2026 is a critical year. Bellwether trials are being scheduled, settlements are being discussed, and the window to file a claim is not unlimited.
This article covers everything: what the lawsuit is about, who qualifies, what settlements could look like, which drugs are included, and how to actually file a claim.
What Is the GLP-1 Lawsuit?
The GLP-1 lawsuit refers to mass tort litigation filed by people who suffered serious injuries after taking GLP-1 receptor agonist drugs, primarily for diabetes management or weight loss.
GLP-1 stands for glucagon-like peptide-1. These drugs mimic a natural hormone to control blood sugar and suppress appetite. They became enormously popular starting around 2021.
The core legal claim is straightforward: drug makers knew, or should have known, that these medications carried risks of devastating gastrointestinal injuries. Plaintiffs argue the companies failed to adequately warn patients and doctors.
The litigation is centered in the Eastern District of Pennsylvania under MDL No. 3094.
| Key Detail | Information |
|---|---|
| MDL Number | MDL-3094 |
| Court | U.S. District Court, Eastern District of Pennsylvania |
| Primary Defendants | Novo Nordisk, Eli Lilly |
| Core Legal Claim | Failure to warn, product liability |
| Drugs Named | Ozempic, Wegovy, Mounjaro, Zepbound, others |
| Cases Filed (est.) | 10,000 plus as of early 2026 |
The number of plaintiffs keeps growing. What started as a few hundred individual lawsuits has become one of the most significant pharmaceutical mass torts in recent memory.
GLP-1 Lawsuit Settlement Amount: What Could Victims Receive?
No official global settlement has been reached in the GLP-1 litigation as of 2026, but legal analysts are watching the bellwether trial outcomes closely for clues about settlement ranges.
In mass tort cases like this, settlement amounts are almost never uniform. They get tiered by injury severity.
Based on patterns from comparable pharmaceutical mass torts like Vioxx and Zantac, GLP-1 settlement tiers could look something like this:
| Injury Tier | Injury Type | Estimated Settlement Range |
|---|---|---|
| Tier 1 (Severe) | Stomach paralysis requiring feeding tube, intestinal surgery, permanent disability | $250,000 to $1,000,000 plus |
| Tier 2 (Significant) | Hospitalization for pancreatitis, gastroparesis diagnosis, extended medical treatment | $50,000 to $250,000 |
| Tier 3 (Moderate) | Documented GI injury with medical treatment but no hospitalization | $10,000 to $50,000 |
| Tier 4 (Minor) | Side effects with minimal documented harm | $1,000 to $10,000 |
These are projections, not guarantees. The actual settlement grid depends entirely on how the first trials go.
Think of bellwether trials like test cases. They’re not binding on every plaintiff, but they tell both sides what a jury thinks the case is worth. That shapes every settlement offer that follows.
Key stat: In the Vioxx litigation, Merck ultimately paid $4.85 billion. GLP-1 litigation involves far more plaintiffs and multiple defendants.
Who Qualifies for the GLP-1 Lawsuit?
You likely qualify for the GLP-1 lawsuit if you took a GLP-1 drug and were diagnosed with a serious gastrointestinal condition that required medical attention.
The requirements are more specific than “I got nauseous.” Courts and attorneys are focused on cases involving documented, serious harm.
You may qualify if you meet ALL of the following:
- You were prescribed or took Ozempic, Wegovy, Mounjaro, Zepbound, Rybelsus, Trulicity, Victoza, Saxenda, or another GLP-1 drug
- You were diagnosed with gastroparesis, pancreatitis, intestinal obstruction, ileus, or another severe GI condition
- Your diagnosis occurred during or after taking the GLP-1 drug
- You have medical records confirming the diagnosis and treatment
- Your injury required hospitalization, surgery, or ongoing medical care
You may also qualify if:
- You developed vision loss or diabetic retinopathy worsening while on Ozempic or semaglutide
- You experienced kidney injury linked to GLP-1 use
- A family member died from complications tied to GLP-1 drug use
People who experienced only mild nausea, temporary bloating, or self-limiting side effects are generally not the focus of current litigation.
GLP-1 Lawsuit Payout Per Person: Realistic Expectations
Individual GLP-1 lawsuit payouts will vary dramatically based on how badly someone was hurt and how well they can document that harm.
The short answer: people with the most severe, best-documented injuries stand to receive the most money.
Here’s what typically factors into individual payout calculations in pharmaceutical mass torts:
| Factor | Impact on Payout |
|---|---|
| Severity of injury | Highest impact. Surgery, feeding tubes, permanent damage = higher tier |
| Duration of drug use | Longer documented use strengthens the causation argument |
| Medical records quality | Clear, detailed records increase case value significantly |
| Lost wages and income | Documented financial loss adds to compensatory damages |
| Age and life expectancy | Younger plaintiffs with permanent injuries often receive more |
| Pain and suffering evidence | Journals, testimony, family witness statements help |
| Prior GI conditions | Pre-existing conditions can reduce or complicate payout |
People sometimes compare personal injury lawsuits to a lottery. That’s not how it works. These are structured negotiations based on documented harm.
The strongest cases are the ones where someone has clear medical records showing they took the drug, got diagnosed with a serious GI condition during or after use, received substantial treatment, and suffered lasting consequences.
Key Takeaway: The GLP-1 lawsuit involves serious injuries at its core. Settlement amounts will range from a few thousand dollars to potentially over a million, depending entirely on the severity and documentation of each individual’s harm.
Ozempic Lawsuit 2026: Where Does It Stand?
The Ozempic lawsuit in 2026 is in an active phase of pretrial litigation, with bellwether cases being prepared for trial in MDL-3094.
Ozempic, made by Novo Nordisk, is the highest-profile drug in this litigation. It was approved for Type 2 diabetes in 2017 and became a cultural phenomenon when its weight loss effects gained massive attention around 2022 and 2023.
The lawsuit alleges Novo Nordisk knew about serious gastrointestinal risks but downplayed them in marketing and labeling to protect billions in annual revenue.
In 2024, Novo Nordisk updated Ozempic’s prescribing information to include more language about gastrointestinal risks. Plaintiffs’ attorneys argue this update proves the company knew more than it disclosed earlier.
2026 Ozempic Litigation Timeline:
| Period | Expected Development |
|---|---|
| Early 2026 | Bellwether trial selections finalized in MDL-3094 |
| Mid-2026 | First bellwether trials begin or are scheduled |
| Late 2026 | Potential global settlement negotiations if plaintiffs win early trials |
| 2027 onwards | Settlement fund distribution if deal is reached |
Ozempic generated over $13 billion in global sales in 2023 alone. Novo Nordisk has enormous financial resources to fight this litigation. But that also means it has enormous resources to fund a settlement when the legal pressure becomes unsustainable.
Ozempic Gastroparesis Lawsuit: The Most Common Injury Claim
Gastroparesis is the single most common injury driving Ozempic lawsuits, and it’s a serious, life-altering condition that plaintiffs say the drug label badly underrepresented.
Gastroparesis literally means “stomach paralysis.” The stomach stops emptying food normally. Instead of food moving through the digestive system within a few hours, it can sit in the stomach for days.
The symptoms are miserable and disabling: severe nausea, vomiting, inability to eat solid food, dangerous weight loss, dehydration, and repeated hospitalizations.
GLP-1 drugs like Ozempic slow gastric emptying as part of how they work. That’s intentional. But the lawsuits claim the degree of slowing in some patients crossed into pathological territory.
Documented impacts of drug-induced gastroparesis:
- Patients required feeding tubes for nutrition
- Some could not work for months or years
- Repeated emergency room visits and hospitalizations
- Some patients developed permanent gastric damage
A 2023 study published in JAMA found that GLP-1 users faced a 9.09 times higher risk of gastroparesis compared to users of other weight loss drugs. That finding became central to many plaintiff lawsuits.
The gastroparesis claims are the most numerous and, in many cases, the most documentable injuries in this litigation.
GLP-1 Pancreatitis Lawsuit: A Separate, Serious Claim
The GLP-1 pancreatitis lawsuit covers patients who developed inflammation of the pancreas, a painful and potentially life-threatening condition, while taking GLP-1 drugs.
Pancreatitis is not the same as gastroparesis. They are two separate injury categories. Pancreatitis involves the pancreas, not the stomach.
The pancreas produces enzymes that help digest food and hormones like insulin. When it becomes inflamed, the results can be severe: intense abdominal pain, fever, nausea, vomiting, and in serious cases, organ damage or death.
The FDA actually flagged a potential link between GLP-1 drugs and pancreatitis as far back as 2013. The question in litigation is whether drug makers adequately communicated that risk to prescribing physicians and patients.
| Pancreatitis Claim Detail | Information |
|---|---|
| FDA Initial Warning Year | 2013 |
| Type of Pancreatitis Alleged | Acute and chronic pancreatitis |
| Primary Drugs Named | Ozempic, Victoza, Byetta, Trulicity |
| Claimed Failure | Inadequate label warnings about pancreatitis risk |
| Potential Severity | Ranges from hospitalization to fatal complications |
Some pancreatitis cases have progressed to pancreatic necrosis, where pancreatic tissue dies. That is a life-threatening emergency with long-term health consequences.
These cases tend to carry high damages because the injuries are severe, documentable, and in many instances, permanently alter quality of life.
GLP-1 Stomach Paralysis Lawsuit: Understanding the Mechanism
The GLP-1 stomach paralysis lawsuit is closely related to the gastroparesis claims but focuses specifically on cases where gastric motility stopped almost entirely, not just slowed.
“Stomach paralysis” is the lay term for what medical records call gastroparesis or gastric dysmotility. For legal purposes, these terms are treated as overlapping.
The mechanism matters in court. GLP-1 drugs work partly by activating receptors in the gut that slow digestion. In a normal therapeutic dose, this creates a feeling of fullness and helps control blood sugar.
In some patients, this mechanism appears to have caused the stomach to essentially stop functioning. Food would accumulate, ferment, and create dangerous conditions requiring emergency intervention.
What stomach paralysis patients experienced:
- Violent, repeated vomiting that couldn’t be controlled at home
- Complete inability to tolerate solid food for weeks or months
- Significant unintended weight loss (beyond the intended therapeutic effect)
- Hospitalizations for dehydration and nutritional deficiency
- In some cases, placement of jejunal feeding tubes to bypass the stomach
Think of it like a traffic jam that started as “slow traffic” and turned into a complete gridlock where nothing moves at all. That’s the core biological argument plaintiffs make about what GLP-1 drugs did to some patients’ digestive systems.
Key Takeaway: Ozempic gastroparesis and stomach paralysis claims represent the largest category of GLP-1 lawsuits in 2026, with the JAMA study showing a 9x elevated risk serving as a pivotal piece of scientific evidence for plaintiffs.
Wegovy Lawsuit: Is It Different From the Ozempic Case?
The Wegovy lawsuit involves the same active ingredient as Ozempic, which is semaglutide, but it targets a different approved use and a different patient population.
Ozempic is approved for Type 2 diabetes. Wegovy is approved for chronic weight management. Both are made by Novo Nordisk and both contain semaglutide.
The legal distinction matters. Wegovy is prescribed to people without diabetes, meaning those patients often have no medical necessity for the GI risks that come with the drug. Their baseline health profiles are different.
Plaintiffs’ attorneys argue that Novo Nordisk aggressively marketed Wegovy to a broad population while underplaying the same gastrointestinal risks that were already emerging from Ozempic data.
| Comparison | Ozempic | Wegovy |
|---|---|---|
| Active Ingredient | Semaglutide | Semaglutide |
| Approved Use | Type 2 Diabetes | Chronic Weight Management |
| Typical Patient | Diabetic | Overweight or Obese, often non-diabetic |
| Dose | Up to 1 mg weekly | Up to 2.4 mg weekly |
| Lawsuit Focus | Failure to warn diabetic patients | Failure to warn weight loss patients |
| Defendant | Novo Nordisk | Novo Nordisk |
The higher approved dose in Wegovy is a key point for some plaintiffs. More semaglutide could mean more gastric slowing, and plaintiffs argue the higher-dose formulation should have carried stronger warnings.
Both Ozempic and Wegovy claims are consolidated under MDL-3094.
Mounjaro Lawsuit 2026: Eli Lilly’s Legal Problem
The Mounjaro lawsuit targets Eli Lilly, a separate pharmaceutical giant, and involves a different drug with a different mechanism than Ozempic.
Mounjaro contains tirzepatide, not semaglutide. It is a dual GIP and GLP-1 receptor agonist, meaning it activates two hormone pathways instead of one. Zepbound is the same tirzepatide drug but approved for weight loss.
The dual mechanism was marketed as an advantage for blood sugar control and weight loss. Plaintiffs argue it also doubles the risk for gastrointestinal injury.
Eli Lilly faces many of the same failure-to-warn allegations as Novo Nordisk, but Mounjaro cases are handled separately because the drug is chemically distinct and the defendant is different.
Mounjaro and Zepbound cases in 2026:
- Lawsuits are being filed in both state and federal court
- Some cases are being coordinated with the Pennsylvania MDL
- Others are being filed separately in Illinois, Eli Lilly’s home state jurisdiction
- Tirzepatide cases often allege pancreatitis, gastroparesis, and intestinal obstruction
Mounjaro hit $5.1 billion in U.S. sales in 2023. Zepbound launched late that year and saw explosive growth through 2024 and 2025. The volume of patients exposed to tirzepatide means the litigation is expected to grow substantially through 2026.
Semaglutide Lawsuit: The Science Behind the Claims
The semaglutide lawsuit refers specifically to cases targeting drugs containing semaglutide, which includes Ozempic, Wegovy, and Rybelsus.
Semaglutide is the active compound that Novo Nordisk developed and holds primary patents on. Understanding why semaglutide is at the center of this litigation requires a quick look at the science.
Semaglutide mimics the GLP-1 hormone. That hormone naturally slows gastric emptying, suppresses appetite, and stimulates insulin release. In therapeutic doses, it works as intended.
The lawsuits argue that semaglutide’s effect on gastric motility was never fully studied for long-term use in certain populations. Clinical trials before approval were not long enough to capture chronic gastroparesis development in many patients.
Scientific evidence cited in semaglutide lawsuits:
- The 2023 JAMA study showing 9.09x higher gastroparesis risk
- FDA Adverse Event Reporting System (FAERS) data showing thousands of reported GI injuries
- Post-market studies showing intestinal obstruction rates higher than pre-approval predictions
- Internal Novo Nordisk documents obtained in discovery showing awareness of GI risk signals
The semaglutide lawsuits are scientific cases at their core. Winning or losing depends heavily on expert witnesses who can explain to juries why the drug causes these injuries and why the warning labels were insufficient.
Key Takeaway: The semaglutide lawsuit and Mounjaro lawsuit involve different drugs and different defendants, so even if you took multiple GLP-1 drugs, you may have claims against multiple pharmaceutical companies.
Novo Nordisk Lawsuit: What the Company Faces
The Novo Nordisk lawsuit puts the Danish pharmaceutical company at the center of the largest GLP-1 litigation, defending two of the most widely prescribed drugs in history.
Novo Nordisk is the world’s most valuable pharmaceutical company by market cap at certain points in recent years, fueled almost entirely by the semaglutide franchise.
Plaintiffs allege that Novo Nordisk:
- Knew from early clinical and post-market data that semaglutide carried serious GI risks
- Downplayed those risks in labeling and marketing materials
- Continued aggressive direct-to-consumer advertising even as adverse event reports mounted
- Updated warning labels only after litigation pressure increased
The company’s defense arguments include:
- FDA approved the labeling, so the warnings were adequate as a matter of law
- GLP-1 drugs save lives in diabetic patients and the benefit-risk balance is positive
- Many plaintiffs have pre-existing GI conditions that caused their symptoms
- Causation between the drug and specific injuries is scientifically contested
This defense strategy is called the “preemption” argument. Drug makers frequently argue that because the FDA approved their label, state law tort claims are preempted by federal law. Courts have split on this argument for years, and it remains a contested issue in GLP-1 litigation.
Novo Nordisk had revenues exceeding $33 billion in 2023, much of it from semaglutide products.
Eli Lilly GLP-1 Lawsuit: A Separate Battle
The Eli Lilly GLP-1 lawsuit centers on Mounjaro and Zepbound, and it runs on a parallel but separate legal track from the Novo Nordisk litigation.
Eli Lilly is headquartered in Indianapolis, Indiana. That matters for plaintiffs who want to file in Eli Lilly’s home jurisdiction rather than consolidate into the Pennsylvania MDL.
The core allegations against Eli Lilly mirror those against Novo Nordisk: failure to warn about serious GI risks, misleading marketing, and prioritizing commercial success over patient safety.
But the Eli Lilly cases have one additional wrinkle. Tirzepatide’s dual-receptor activity was heavily marketed as superior to single-GLP-1 drugs. Plaintiffs argue that marketing created a false sense that Mounjaro was a safer, more targeted option when, in fact, the dual mechanism may increase GI injury risk.
| Eli Lilly Case Factor | Detail |
|---|---|
| Drugs Involved | Mounjaro (tirzepatide), Zepbound (tirzepatide) |
| Approved Uses | Mounjaro: Type 2 Diabetes; Zepbound: Weight Loss |
| Active Ingredient | Tirzepatide |
| Mechanism | Dual GIP/GLP-1 receptor agonist |
| Defendant HQ | Indianapolis, Indiana |
| Key Allegation | Failure to warn, misleading superiority claims |
Eli Lilly’s 2023 tirzepatide revenue exceeded $5 billion globally. The company is financially capable of mounting a prolonged legal defense but also financially motivated to settle before jury verdicts set unfavorable precedents.
Is the GLP-1 Lawsuit a Class Action or a Mass Tort?
The GLP-1 lawsuit is a mass tort, not a traditional class action, and that distinction has a direct impact on how much money individual plaintiffs can receive.
In a class action lawsuit, everyone gets roughly the same settlement amount. Individual circumstances matter less. The payout is divided more or less equally after attorneys take their fees.
In a mass tort like the GLP-1 litigation, each plaintiff has their own individual case. They are centralized in an MDL for pretrial purposes, but each person’s compensation is calculated based on their specific injuries, medical costs, lost income, and suffering.
Class Action vs. Mass Tort: What It Means for You
| Feature | Class Action | Mass Tort (GLP-1 Case) |
|---|---|---|
| Individual payout | Usually small (sometimes a few dollars) | Potentially large, based on individual harm |
| Case individuality | One outcome applies to everyone | Each case evaluated separately |
| Settlement structure | Single fund divided equally | Tiered by injury severity |
| Your role | Passive participant | Active party with your own case value |
| MDL involvement | Not applicable | Yes, cases coordinated in MDL-3094 |
Being in a mass tort is both better and more demanding than a class action. You can potentially receive much more money. You also have to provide your own medical records, prove your specific injuries, and work with an attorney on your individual claim.
Ozempic Lawsuit MDL Update 2026: What’s Happening in Court
The Ozempic lawsuit MDL update for 2026 shows an active litigation landscape with thousands of cases consolidated and the first bellwether trials approaching.
MDL-3094 in the Eastern District of Pennsylvania is being overseen by U.S. District Judge Gene E.K. Pratter. The court has been managing discovery, expert witness disclosures, and case management orders throughout 2024 and 2025.
2026 MDL Status Snapshot:
| MDL Milestone | Status in 2026 |
|---|---|
| Cases filed in MDL | 10,000 plus and growing |
| Bellwether case selection | Underway in early 2026 |
| Expert discovery | Substantially complete |
| First trials | Scheduled or being scheduled in 2026 |
| Settlement talks | Preliminary, tied to trial outcomes |
| Science Day hearings | Completed in 2024-2025 |
Bellwether trials are the critical next step. These are the cases handpicked by both sides to go to trial first. They test the evidence, the expert witnesses, and jury reactions.
If plaintiffs win the first bellwether trials convincingly, Novo Nordisk and Eli Lilly face enormous pressure to settle. If defendants win, the calculus shifts. Either way, 2026 is when GLP-1 litigation stops being theoretical and starts producing real verdicts.
Key Takeaway: The GLP-1 mass tort in 2026 is at a pivotal stage, with bellwether trials in MDL-3094 set to establish how juries value these injuries, directly shaping whether and how much defendants will pay to settle the broader litigation.
GLP-1 Lawsuit Filing Deadline: Don’t Wait Too Long
The GLP-1 lawsuit filing deadline depends on the statute of limitations in your state, and in most states, you have between 2 and 3 years from the date of injury or diagnosis.
This is not a case where you can assume there’s plenty of time. Statutes of limitations are hard deadlines. Miss them, and you lose your right to sue permanently, regardless of how strong your case is.
State statute of limitations examples for product liability claims:
| State | Statute of Limitations |
|---|---|
| California | 2 years from date of injury |
| Texas | 2 years from date of injury |
| Florida | 2 years (changed from 4 years effective 2023) |
| New York | 3 years from date of injury |
| Pennsylvania | 2 years from date of injury |
| Illinois | 2 years from date of injury |
| Ohio | 2 years from date of injury |
The “discovery rule” can extend this in some states. Under the discovery rule, the clock starts when you knew, or reasonably should have known, that your injury was caused by the drug. If you took Ozempic in 2022 and weren’t diagnosed with gastroparesis until 2024, your clock may have started in 2024.
But relying on the discovery rule is risky. Courts interpret it differently. The safest approach is to assume your deadline is running and act now.
GLP-1 Lawsuit How to File: A Practical Step-by-Step Guide
Filing a GLP-1 lawsuit starts with gathering your medical records and connecting with an attorney who handles pharmaceutical mass torts.
You do not file directly with the MDL court yourself. Individual plaintiffs work through attorneys who manage the filing and MDL enrollment process on their behalf.
Step-by-step process for filing a GLP-1 claim:
- Gather your pharmacy records: Get documentation showing you were prescribed and filled prescriptions for Ozempic, Wegovy, Mounjaro, or another GLP-1 drug. Pharmacy printouts or insurance records work.
- Get your medical records: You need records showing your diagnosis. Gastroparesis, pancreatitis, intestinal obstruction, and other GI injuries must be documented by a doctor, hospital, or specialist.
- Document your treatment history: Emergency room visits, hospitalizations, procedures, feeding tube placements, specialist referrals, and ongoing treatment all strengthen your case.
- Calculate your financial losses: Document medical bills, lost wages, out-of-pocket costs, and any future projected medical expenses.
- Contact a mass tort attorney: Look for attorneys or law firms with specific experience in pharmaceutical litigation and MDL cases. Most work on contingency, meaning no upfront costs to you.
- Case evaluation: Your attorney reviews your records, assesses your case strength, and determines whether you have a viable claim.
- Filing: Your attorney files your complaint and coordinates enrollment in MDL-3094 or the appropriate state court, depending on your situation.
The contingency fee standard in mass tort cases is typically 33% to 40% of the recovery. This is negotiable in some cases, and the fee structure should be discussed clearly before you sign any representation agreement.
The stronger your records, the faster this process moves. If your medical records are thin or disorganized, your attorney may recommend getting a records review done before anything else.
Frequently Asked Questions
What is the GLP-1 lawsuit about?
The GLP-1 lawsuit is about people who suffered serious injuries, including stomach paralysis, pancreatitis, and intestinal blockages, after taking GLP-1 drugs like Ozempic, Wegovy, and Mounjaro.
Plaintiffs allege that drug makers Novo Nordisk and Eli Lilly knew about these risks but failed to adequately warn patients and doctors.
The litigation is consolidated in MDL-3094 in the Eastern District of Pennsylvania, with thousands of cases actively pending in 2026.
How much money can I get from a GLP-1 lawsuit settlement?
Settlement amounts in GLP-1 lawsuits are expected to range from a few thousand dollars for minor documented injuries up to $1 million or more for severe, permanent cases.
No global settlement has been reached as of 2026, so individual amounts depend on bellwether trial outcomes and each plaintiff’s injury severity.
People with surgical interventions, permanent GI damage, or significant financial losses are expected to receive the highest compensation.
Do I qualify for the GLP-1 lawsuit if I only took Ozempic for weight loss?
Yes, you may qualify even if you took Ozempic off-label for weight loss rather than for diabetes.
What matters most is whether you were diagnosed with a serious injury like gastroparesis, pancreatitis, or intestinal obstruction during or after your use of the drug.
Your attorney will evaluate your specific circumstances, the duration of use, and the documentation of your injury to determine case strength.
What is the filing deadline for the GLP-1 lawsuit in 2026?
The filing deadline varies by state, but most states allow 2 to 3 years from the date of your injury or diagnosis to file a product liability claim.
Some states apply the discovery rule, which starts the clock when you first learned your injury was connected to the drug.
Waiting too long is the single biggest mistake claimants make. Once the statute of limitations expires, the right to sue is permanently lost.
Is the GLP-1 lawsuit a class action or a mass tort?
The GLP-1 lawsuit is a mass tort, not a class action, which means each plaintiff has their own case with individual compensation based on their specific injuries.
This is significantly better for seriously injured people than a class action, where payouts are typically small and divided equally.
Cases are coordinated in MDL-3094 for pretrial efficiency, but each claimant’s case value is calculated independently based on injury severity, medical costs, and documented harm.
What You Should Do Right Now
The GLP-1 lawsuit is at a turning point in 2026. Bellwether trials are happening, settlements are being discussed, and the longer you wait, the more complicated your claim could become.
If you took Ozempic, Wegovy, Mounjaro, or any GLP-1 drug and were seriously hurt, start pulling your records together now. Pharmacy records, hospital visits, specialist diagnoses, and bills all matter.
Find a mass tort attorney with pharmaceutical litigation experience. Most offer free case evaluations, and you pay nothing unless you win. Time is the one thing you cannot get back once a statute of limitations expires.
